User profiles for R. Mina
Rusty John Lloyd MinaKAIST Verified email at kaist.ac.kr Cited by 76 |
Pediatric lupus—are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?
R Mina, HI Brunner - Rheumatic Disease Clinics, 2010 - rheumatic.theclinics.com
An estimated 10% to 20% of patients experience the onset of systemic lupus erythematosus
(SLE) before adulthood. More precise estimates are difficult due to a lack of a clear age limit …
(SLE) before adulthood. More precise estimates are difficult due to a lack of a clear age limit …
[HTML][HTML] Update on differences between childhood-onset and adult-onset systemic lupus erythematosus
R Mina, HI Brunner - Arthritis research & therapy, 2013 - Springer
… by serum osteo calcin (Spearman rank correlation coefficient r = –0.34, P <0.0001) [35]. …
doi:10.1186/ar4256 Cite this article as: Mina R, Brunner HI: Update on differences between …
doi:10.1186/ar4256 Cite this article as: Mina R, Brunner HI: Update on differences between …
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European …
…, K Yong, F Gay, H Einsele, R Mina… - The Lancet …, 2023 - thelancet.com
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
…, M Cavo, A Belotti, A Broijl, F Gay, R Mina… - … England Journal of …, 2024 - Mass Medical Soc
Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …
[HTML][HTML] Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
…, M Offidani, JJ Lahuerta, AM Liberati, R Mina… - …, 2013 - ncbi.nlm.nih.gov
Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these
patients, treatment-related side effects are frequent and full drug doses difficult to tolerate. …
patients, treatment-related side effects are frequent and full drug doses difficult to tolerate. …
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial …
…, P Omedé, R Marasca, F Morabito, R Mina… - Journal of Clinical …, 2014 - iris.unito.it
Purpose: Bortezomib-melphalan-prednisone (VMP) has improved overall survival in
multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction …
multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction …
Forget-free continual learning with winning subnetworks
Inspired by Lottery Ticket Hypothesis that competitive subnetworks exist within a dense
network, we propose a continual learning method referred to as Winning SubNetworks (WSN), …
network, we propose a continual learning method referred to as Winning SubNetworks (WSN), …
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus
R Mina, E Von Scheven, SP Ardoin… - Arthritis care & …, 2012 - Wiley Online Library
… Mina and von Scheven contributed equally to this work. … Nezhad ST, Sepaskhah R.
Correlation of clinical and pathological findings in patients with lupus nephritis: a five-year …
Correlation of clinical and pathological findings in patients with lupus nephritis: a five-year …
Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis
HI Brunner, MR Bennett, R Mina, M Suzuki… - Arthritis & …, 2012 - Wiley Online Library
… (r ≥ |0.2|). In addition, some strong correlations between TF levels and levels of other
biomarkers were observed (r = 0.74, P < 0.0001 for the correlation between TF and CP levels; r = …
biomarkers were observed (r = 0.74, P < 0.0001 for the correlation between TF and CP levels; r = …
Predicting survival in malignant mesothelioma
…, N Olsen, H Alfonso, A Reid, R Mina… - European …, 2011 - Eur Respiratory Soc
Malignant mesothelioma (MM) of the pleura or peritoneum is a universally fatal disease
attracting an increasing range of medical interventions and escalating healthcare costs. …
attracting an increasing range of medical interventions and escalating healthcare costs. …